Proposed algorithm for diagnosis and classification of Ph-negative myeloproliferative disease in patients with Budd-Chiari syndrome or portal vein thrombosis based on JAK2V617F testing, followed by RCM determination in JAK2V617F-positive patients, and BMB and EEC assessment in JAK2V617F-negative patients. Values in italics represent distribution of patients of this cohort.